Praxis Precision (PRAX) Medicines announced that that it will present preclinical and clinical data from three of its epilepsy programs at the American Epilepsy Society, AES, Annual Meeting, being ...
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Gain Therapeutics (GANX – Research Report), retaining the price target of ...
Dundee University spin-out Exscientia has been taken over by US pharmaceutical rival Recursion, in a deal worth around £500m. The firm was delisted from the NASDAQ stock exchange on Wednesday after ...
Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, ...
Novartis (NVS) acquires gene therapy developer Kate Therapeutics for up to $1.1B, expanding expertise in neuromuscular diseases. Read more here.
Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.
Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 ...
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback